All Wheel Drive Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The allergic rhinitis market size has grown steadily in recent years. It will grow from $15.22 billion in 2024 to $15.74 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to allergen exposure, environmental changes, public awareness, incresing pollution, research and developments on allergic rhinitis, rising disposable incomes.

The allergic rhinitis market size is expected to see steady growth in the next few years. It will grow to $18.49 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to demand for preventive treatments, aging population, urbanization, health care spending. Major trends in the forecast period include biologics and monoclonal antibodies, digital health solutions, allergen avoidance strategies, pediatric allergic rhinitis, allergen detection technology.

High levels of air pollution and climate change are expected to significantly drive the growth of the allergic rhinitis market. Air pollution, characterized by harmful substances in the atmosphere, adversely affects respiratory health, contributing to the increasing prevalence of allergic rhinitis. Climate change, with its long-term alterations in temperature and precipitation, can exacerbate the frequency and intensity of allergens like pollen, which in turn worsens the symptoms of allergic rhinitis. This connection underscores the rising concern about environmental factors influencing respiratory conditions. For instance, in August 2024, the United States Environmental Protection Agency (EPA) reported that approximately 66 million tons of pollutants were released into the atmosphere across the U.S. in 2023. These elevated pollution levels, along with changing climate patterns, are expected to lead to higher incidences of allergic rhinitis, thereby driving the growth of the market for treatments and management solutions.

The increase in corticosteroid treatment for allergic rhinitis is expected to significantly drive the growth of the allergic rhinitis market. Corticosteroids, commonly used to reduce inflammation in the nasal passages, are effective in relieving the symptoms of allergic rhinitis, such as congestion, sneezing, and itching. This treatment approach has become increasingly popular due to its ability to control inflammation and improve the quality of life for patients. For example, in September 2023, the American Society for Clinical Pharmacology and Therapeutics reported that oral corticosteroid use averaged 6.8% in the U.S., 17.5% in Taiwan, and 2.2% in Denmark, with annual increases ranging from 0.1% to 0.17%. The majority of these prescriptions were for short bursts, typically for healthy adults with self-limited conditions like respiratory infections. As the use of corticosteroids continues to rise, it is expected to further contribute to the expansion of the allergic rhinitis market by enhancing treatment options and improving patient outcomes.

Prominent players within the allergic rhinitis market are actively engaged in the development of cutting-edge medications to maintain their market presence. For instance, in August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company based in the UK, and Glenmark Specialty S.A., a pharmaceutical company headquartered in Switzerland, received approval from the United States Food and Drug Administration (FDA), a federal agency based in the US, for their product known as Ryaltris. Ryaltris represents the first fixed-dose combination medication designed to alleviate both nasal and ocular symptoms of seasonal allergic rhinitis. It is conveniently administered as a nasal spray for adult and pediatric patients aged 12 and above. Notably, the relief from nasal symptoms begins within 15 minutes of the initial dose.

In January 2022, Glenmark Specialty S.A., a pharmaceutical company headquartered in Switzerland, established a partnership with Lotus International Pte. Ltd., a pharmaceutical company based in Singapore. Through this collaboration, Glenmark is set to introduce Ryaltris, an innovative nasal spray designed for allergic rhinitis treatment, into the markets of Singapore, Hong Kong, and Vietnam. Under this arrangement, Glenmark will be responsible for the manufacturing and supply of Ryaltris, while Lotus will oversee the commercialization of Ryaltris in these regions.

Major companies operating in the allergic rhinitis market are Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Limited, Menarini Group, Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Limited, Endo Pharmaceuticals Inc., Zydus Lifesciences Ltd., Lupin Limited, Glenmark Pharma Ltd., Almirall S.A., Kyowa Kirin Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Akorn Inc.

North America was the largest region in the allergic rhinitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in allergic rhinitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the allergic rhinitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allergic rhinitis market consists of revenues earned by entities by providing treatments such as alternative therapies, surgeries and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The allergic rhinitis market also includes sales of allergy pills and injections that are used for the treatment of the disease. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Allergic rhinitis is a condition characterized by an allergic response that triggers nasal inflammation due to allergens like pollen, dust, mold, or pet dander. This allergic reaction leads to symptoms such as sneezing, nasal congestion, an itchy nose, and a sore throat. The management of allergic rhinitis involves the use of a range of allergy medications available in different dosage forms to alleviate these bothersome symptoms.

Allergic rhinitis can be categorized into several types, including seasonal allergic rhinitis (SAR), perennial allergic rhinitis, and occupational allergic rhinitis. SAR is characterized by the rapid onset and resolution of symptoms, often associated with allergens like pollen. The treatments for allergic rhinitis encompass various options such as antihistamines, corticosteroids, immunotherapy, and decongestants. Diagnosis and evaluation may involve different tests like skin tests, IgE radioallergosorbent tests, and complete blood counts. These treatments are administered through various routes, including oral and nasal administration. Moreover, they are accessible through diverse distribution channels such as hospital pharmacies, retail pharmacies, and online stores.

The allergic rhinitis market research report is one of a series of new reports that provides allergic rhinitis market statistics, including allergic rhinitis industry global market size, regional shares, competitors with an allergic rhinitis market share, detailed allergic rhinitis market segments, market trends and opportunities and any further data you may need to thrive in the allergic rhinitis industry. This allergic rhinitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.